Mechanisms of action of cyclosporine: considerations for the treatment of autoimmune diseases.
Hess
A D
AD
Bone Marrow Transplant Unit, Johns Hopkins University, Baltimore, Maryland 21205.
D000591:Amino Acid Isomerases / Q000502:physiology; D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy*; D002147:Calmodulin / Q000502:physiology; D002352:Carrier Proteins / Q000502:physiology; D016572:Cyclosporine / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007109:Immunity / Q000187:drug effects; D007376:Interleukin-2 / Q000096:biosynthesis; D008213:Lymphocyte Activation / Q000187:drug effects; D008222:Lymphokines / Q000096:biosynthesis; D019696:Peptidylprolyl Isomerase; D015375:Receptors, Interleukin-2 / Q000378:metabolism; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D002147:Calmodulin; D002352:Carrier Proteins; D007376:Interleukin-2; D008222:Lymphokines; D015375:Receptors, Interleukin-2; D016572:Cyclosporine; D000591:Amino Acid Isomerases; D019696:Peptidylprolyl Isomerase